ofloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, nalidixic acid derivatives 1981 82419-36-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gailuoxian
  • ofloxacine
  • oxaldin
  • prifloxcin
  • prifloxin
  • ofloxacin
  • ofloxacin hydrochloride
  • ofloxacin HCl
A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
  • Molecular weight: 361.37
  • Formula: C18H20FN3O4
  • CLOGP: -0.26
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 73.32
  • ALOGS: -2.40
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.54 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 64 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 31.62 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.90 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 100 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.437 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.080 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 9.705 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.690 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 87.320 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 86.750 % High 1
herg hERG pIC50 4.280 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 0.982 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.097 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 86.620 % High 1
kinase-safety-class GRK2,PDK1,PDK2,PDK4 4
kinase-selectivity-class ACVR2B,AXL,BRAF,CAMK2D,CDK9,DYRK1B,EIF2AK3,GRK2,MAPK7,PDK4,PRKDC,SIK2,STK33,TEK,TTK 15
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.455 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 9.268 High 1
mh-clint Mouse hepatocyte intrinsic clearance 2.218 High 1
mppb Mouse plasma protein binding (% unbound) 83.930 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 16.866 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 87.320 % High 1
rat-kpuu-brain Rat brain Kpuu 0.068 % High 1
rh-clint Rat hepatocyte intrinsic clearance 0.953 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 90.560 % High 1
rppb Rat plasma protein binding (% unbound) 72.910 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 885.116 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1990 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endophthalmitis 113.26 16.59 34 8748 4651 90615014
Toxic anterior segment syndrome 93.80 16.59 25 8757 2225 90617440
Eye pain 89.86 16.59 55 8727 44113 90575552
Acute kidney injury 84.91 16.59 128 8654 320259 90299406
Corneal perforation 79.24 16.59 17 8765 596 90619069
Drug reaction with eosinophilia and systemic symptoms 73.84 16.59 48 8734 42710 90576955
Hypopyon 72.48 16.59 17 8765 897 90618768
Cholestasis 70.78 16.59 44 8738 36255 90583410
Rash maculo-papular 68.36 16.59 45 8737 40888 90578777
Toxic epidermal necrolysis 54.89 16.59 36 8746 32492 90587173
Visual acuity reduced 52.38 16.59 31 8751 23379 90596286
Corneal deposits 51.74 16.59 11 8771 369 90619296
Eosinophilia 51.64 16.59 33 8749 28500 90591165
Corneal oedema 51.19 16.59 15 8767 1886 90617779
Gingival ulceration 50.24 16.59 13 8769 1031 90618634
Non-cardiogenic pulmonary oedema 48.19 16.59 13 8769 1211 90618454
Cataract 47.77 16.59 46 8736 72046 90547619
Corneal infiltrates 47.70 16.59 9 8773 162 90619503
Tendon disorder 45.82 16.59 19 8763 6681 90612984
Corneal erosion 45.14 16.59 10 8772 408 90619257
Drug resistance 44.91 16.59 31 8751 30418 90589247
Tendonitis 44.44 16.59 27 8755 21345 90598320
Encephalopathy 41.34 16.59 35 8747 46409 90573256
Acute generalised exanthematous pustulosis 41.12 16.59 22 8760 13681 90605984
Keratitis fungal 39.86 16.59 8 8774 201 90619464
Agranulocytosis 38.83 16.59 30 8752 34972 90584693
Psychotic disorder due to a general medical condition 38.18 16.59 8 8774 250 90619415
Tendon pain 37.50 16.59 14 8768 3734 90615931
Stevens-Johnson syndrome 36.62 16.59 27 8755 29349 90590316
Corneal scar 36.21 16.59 7 8775 144 90619521
Renal necrosis 33.99 16.59 6 8776 73 90619592
Ocular hyperaemia 33.26 16.59 27 8755 33771 90585894
Eye irritation 33.14 16.59 27 8755 33951 90585714
Toxic skin eruption 32.98 16.59 20 8762 15754 90603911
Necrosis 32.96 16.59 15 8767 6595 90613070
International normalised ratio increased 32.87 16.59 31 8751 47285 90572380
Retinal pigment epithelial tear 32.13 16.59 7 8775 264 90619401
Prothrombin time ratio decreased 31.93 16.59 9 8773 986 90618679
Ulcerative keratitis 31.30 16.59 12 8770 3441 90616224
Periodontal disease 31.16 16.59 10 8772 1702 90617963
Tendon rupture 31.03 16.59 16 8766 9227 90610438
Drug interaction 30.18 16.59 76 8706 276377 90343288
Periodontitis 30.02 16.59 12 8770 3841 90615824
Hepatocellular injury 28.22 16.59 23 8759 28935 90590730
Face oedema 28.10 16.59 21 8761 23297 90596368
Photophobia 27.53 16.59 20 8762 21249 90598416
Renal failure 27.28 16.59 47 8735 130960 90488705
Infusion related reaction 27.21 16.59 4 8778 416776 90202889
Vascular purpura 26.98 16.59 9 8773 1729 90617936
Hyperthermia 26.61 16.59 15 8767 10320 90609345
Anuria 26.46 16.59 17 8765 14801 90604864
Joint swelling 26.40 16.59 8 8774 503292 90116373
Intraocular pressure increased 25.92 16.59 13 8769 7080 90612585
Illusion 25.56 16.59 8 8774 1256 90618409
Keratoplasty 24.73 16.59 3 8779 0 90619665
Visual impairment 24.37 16.59 45 8737 132320 90487345
Retinal vasculitis 24.00 16.59 8 8774 1533 90618132
Dermatitis bullous 23.96 16.59 14 8768 10302 90609363
Corneal opacity 23.70 16.59 7 8775 904 90618761
Vitritis 23.64 16.59 8 8774 1606 90618059
Clostridium difficile colitis 23.50 16.59 20 8762 26686 90592979
Sinonasal papilloma 22.95 16.59 4 8778 45 90619620
Hepatic cytolysis 22.91 16.59 21 8761 30895 90588770
Keratolysis exfoliativa acquired 22.65 16.59 3 8779 3 90619662
Acquired haemophilia 22.60 16.59 7 8775 1062 90618603
Retinal oedema 22.55 16.59 7 8775 1069 90618596
Anterior segment ischaemia 22.35 16.59 4 8778 53 90619612
Eye infection 22.17 16.59 15 8767 14239 90605426
Corneal disorder 21.80 16.59 8 8774 2034 90617631
Conjunctival hyperaemia 21.71 16.59 9 8773 3160 90616505
Lenticular opacities 21.20 16.59 5 8777 270 90619395
Pyelonephritis 20.91 16.59 17 8765 21299 90598366
Hepatitis acute 20.71 16.59 13 8769 10874 90608791
Anterior chamber cell 20.67 16.59 6 8776 730 90618935
Thrombocytopenia 20.32 16.59 55 8727 208670 90410995
Gastroenteritis 20.01 16.59 19 8763 29210 90590455
Pupillary block 19.90 16.59 3 8779 12 90619653
Anaemia 19.81 16.59 77 8705 352725 90266940
Keratitis 19.68 16.59 9 8773 3997 90615668
Vision blurred 19.68 16.59 37 8745 110256 90509409
Vitreous floaters 19.55 16.59 11 8771 7538 90612127
Conjunctivitis 19.51 16.59 18 8764 26688 90592977
Reversible cerebral vasoconstriction syndrome 19.42 16.59 9 8773 4121 90615544
Type I hypersensitivity 19.37 16.59 9 8773 4146 90615519
Shock haemorrhagic 19.32 16.59 13 8769 12232 90607433
Gamma-glutamyltransferase increased 19.28 16.59 21 8761 37931 90581734
Eye inflammation 19.15 16.59 11 8771 7840 90611825
Drug hypersensitivity 19.00 16.59 92 8690 463517 90156148
Mucosal erosion 18.85 16.59 7 8775 1838 90617827
Pathogen resistance 18.81 16.59 11 8771 8104 90611561
Corneal epithelium defect 18.32 16.59 5 8777 486 90619179
Hepatitis cholestatic 18.27 16.59 11 8771 8550 90611115
Abdominal discomfort 18.13 16.59 12 8770 477316 90142349
Factor V inhibition 17.96 16.59 4 8778 167 90619498
Meningitis aseptic 17.90 16.59 10 8772 6763 90612902
Oral herpes 17.82 16.59 19 8763 33505 90586160
Confusional state 17.55 16.59 79 8703 386126 90233539
Cutaneous vasculitis 17.34 16.59 10 8772 7183 90612482
Iridocyclitis 17.28 16.59 8 8774 3653 90616012
Central nervous system immune reconstitution inflammatory response 17.19 16.59 3 8779 34 90619631
Cardioactive drug level increased 17.11 16.59 7 8775 2377 90617288
Aortic dissection 17.02 16.59 7 8775 2410 90617255
Contraindicated product administered 16.93 16.59 5 8777 320134 90299531
Hepatitis 16.89 16.59 27 8755 70712 90548953
Extensor plantar response 16.76 16.59 6 8776 1421 90618244
Blepharitis 16.65 16.59 8 8774 3968 90615697
Swelling 16.65 16.59 10 8772 419048 90200617
Metamorphopsia 16.64 16.59 6 8776 1451 90618214

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 146.44 15.01 96 8440 41979 42570820
Tendonitis 82.27 15.01 40 8496 9854 42602945
Type 2 lepra reaction 76.20 15.01 17 8519 338 42612461
Ulcerative keratitis 73.65 15.01 24 8512 2064 42610735
Eye pain 69.48 15.01 43 8493 16987 42595812
Toxic epidermal necrolysis 69.40 15.01 51 8485 26699 42586100
Hepatocellular injury 67.96 15.01 48 8488 23630 42589169
Cholestasis 66.34 15.01 54 8482 32825 42579974
Rash maculo-papular 58.19 15.01 53 8483 37450 42575349
Agranulocytosis 52.93 15.01 46 8490 30566 42582233
Endophthalmitis 52.77 15.01 23 8513 4410 42608389
Tendon pain 52.32 15.01 21 8515 3279 42609520
Corneal oedema 51.40 15.01 17 8519 1531 42611268
Keratitis fungal 49.72 15.01 11 8525 210 42612589
Acute kidney injury 49.08 15.01 173 8363 367164 42245635
Eosinophilia 46.22 15.01 44 8492 32855 42579944
Hyperacusis 45.85 15.01 14 8522 973 42611826
Tendon rupture 42.36 15.01 24 8512 8059 42604740
Corneal deposits 38.14 15.01 9 8527 231 42612568
Eye inflammation 36.05 15.01 16 8520 3202 42609597
Hepatic cytolysis 36.00 15.01 35 8501 26809 42585990
Visual acuity reduced 35.75 15.01 29 8507 17521 42595278
Laryngeal haematoma 35.67 15.01 8 8528 163 42612636
Tendon disorder 35.25 15.01 16 8520 3373 42609426
Chronic fatigue syndrome 34.87 15.01 9 8527 337 42612462
Corneal opacity 33.33 15.01 10 8526 655 42612144
Motion sickness 32.39 15.01 8 8528 250 42612549
Skin hyperpigmentation 29.13 15.01 15 8521 4166 42608633
Haemolytic anaemia 28.93 15.01 22 8514 12105 42600694
Corneal epithelium defect 28.49 15.01 8 8528 414 42612385
Intraocular pressure increased 28.16 15.01 17 8519 6416 42606383
Purpura 27.13 15.01 21 8515 11858 42600941
Distal intestinal obstruction syndrome 27.04 15.01 8 8528 499 42612300
Prostatitis 26.04 15.01 16 8520 6232 42606567
Corneal perforation 25.96 15.01 7 8529 311 42612488
Retinal pigment epithelial tear 25.62 15.01 7 8529 327 42612472
Corneal thinning 25.17 15.01 6 8530 161 42612638
Corneal disorder 24.95 15.01 9 8527 1050 42611749
Vascular purpura 24.91 15.01 11 8525 2175 42610624
Cross sensitivity reaction 24.29 15.01 10 8526 1665 42611134
Hyperthermia 23.98 15.01 20 8516 12554 42600245
Upper airway obstruction 23.51 15.01 8 8528 786 42612013
Anterior chamber cell 23.29 15.01 7 8529 461 42612338
Aqueous humour leakage 22.55 15.01 3 8533 0 42612799
Toxic skin eruption 22.45 15.01 20 8516 13710 42599089
Cataract 22.23 15.01 29 8507 30575 42582224
Sudden infant death syndrome 21.30 15.01 6 8530 314 42612485
Muscle rupture 20.68 15.01 10 8526 2430 42610369
Red blood cell vacuolisation 20.47 15.01 3 8533 3 42612796
Tendon discomfort 20.28 15.01 6 8530 374 42612425
Hepatitis 20.03 15.01 26 8510 27274 42585525
Ocular hyperaemia 19.88 15.01 20 8516 15943 42596856
Eyelid oedema 19.78 15.01 13 8523 5682 42607117
Corneal infiltrates 19.78 15.01 5 8531 172 42612627
Vitreous haemorrhage 19.56 15.01 10 8526 2737 42610062
Muscle contractions involuntary 19.27 15.01 9 8527 2025 42610774
Toxic anterior segment syndrome 19.00 15.01 8 8528 1408 42611391
Fibrin 18.94 15.01 3 8533 7 42612792
Hypopyon 18.26 15.01 6 8530 529 42612270
Rash morbilliform 18.24 15.01 11 8525 4142 42608657
Vasculitis necrotising 18.16 15.01 7 8529 981 42611818
Haematoma 17.98 15.01 25 8511 27998 42584801
Pudendal canal syndrome 17.93 15.01 3 8533 11 42612788
Idiopathic orbital inflammation 17.72 15.01 4 8532 84 42612715
Tuberculoma of central nervous system 17.71 15.01 5 8531 264 42612535
Staphylococcal infection 17.64 15.01 29 8507 37614 42575185
Dysaesthesia 17.31 15.01 9 8527 2548 42610251
Keratitis 17.20 15.01 8 8528 1783 42611016
Atrophy 17.10 15.01 7 8529 1148 42611651
Corneal abrasion 17.06 15.01 5 8531 302 42612497
Myalgia 17.04 15.01 50 8486 96030 42516769
Pustule 16.96 15.01 7 8529 1172 42611627
Acute febrile neutrophilic dermatosis 16.81 15.01 8 8528 1876 42610923
Neuralgia 16.64 15.01 23 8513 25624 42587175
Target skin lesion 16.20 15.01 4 8532 125 42612674
Death 16.19 15.01 45 8491 471140 42141659
Sideroblastic anaemia 16.17 15.01 5 8531 362 42612437
Intra-abdominal haemorrhage 16.17 15.01 9 8527 2919 42609880
International normalised ratio increased 16.05 15.01 32 8504 48136 42564663
Localised oedema 15.87 15.01 10 8526 4068 42608731
Bicytopenia 15.47 15.01 9 8527 3175 42609624
Orchitis 15.46 15.01 8 8528 2243 42610556
Pinguecula 15.45 15.01 3 8533 29 42612770
Immune reconstitution inflammatory syndrome 15.06 15.01 14 8522 10129 42602670

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 216.24 14.06 139 15744 81956 110491460
Endophthalmitis 153.92 14.06 54 15829 8133 110565283
Acute kidney injury 133.16 14.06 286 15597 635144 109938272
Cholestasis 130.97 14.06 93 15790 64425 110508991
Rash maculo-papular 125.88 14.06 96 15787 74126 110499290
Toxic epidermal necrolysis 122.66 14.06 85 15798 56642 110516774
Tendonitis 113.05 14.06 61 15822 26022 110547394
Toxic anterior segment syndrome 106.05 14.06 33 15850 3421 110569995
Eye pain 105.80 14.06 74 15809 50025 110523391
Corneal oedema 104.54 14.06 32 15851 3141 110570275
Corneal perforation 100.08 14.06 24 15859 932 110572484
Eosinophilia 91.82 14.06 72 15811 57864 110515552
Hepatocellular injury 91.39 14.06 68 15815 50574 110522842
Type 2 lepra reaction 84.86 14.06 18 15865 397 110573019
Agranulocytosis 83.60 14.06 70 15813 61690 110511726
Ulcerative keratitis 80.35 14.06 29 15854 4737 110568679
Corneal deposits 78.37 14.06 18 15865 578 110572838
Keratitis fungal 78.22 14.06 17 15866 422 110572994
Hypopyon 76.25 14.06 21 15862 1419 110571997
Tendon pain 75.85 14.06 30 15853 6296 110567120
Tendon disorder 71.10 14.06 31 15852 8306 110565110
Tendon rupture 64.01 14.06 34 15849 14044 110559372
Visual acuity reduced 62.10 14.06 45 15838 32128 110541288
Retinal pigment epithelial tear 59.90 14.06 14 15869 486 110572930
Hepatic cytolysis 57.72 14.06 54 15829 54999 110518417
Corneal infiltrates 53.22 14.06 12 15871 354 110573062
Vascular purpura 52.73 14.06 20 15863 3751 110569665
Toxic skin eruption 52.00 14.06 38 15845 27477 110545939
Corneal opacity 51.56 14.06 15 15868 1236 110572180
Hyperthermia 51.01 14.06 34 15849 21238 110552178
Drug resistance 49.18 14.06 50 15833 56324 110517092
International normalised ratio increased 46.83 14.06 60 15823 86712 110486704
Haemolytic anaemia 44.38 14.06 31 15852 20889 110552527
Prothrombin time ratio decreased 43.84 14.06 14 15869 1578 110571838
Corneal scar 43.21 14.06 10 15873 332 110573084
Anterior chamber cell 43.16 14.06 13 15870 1208 110572208
Intraocular pressure increased 43.15 14.06 24 15859 10852 110562564
Gingival ulceration 42.86 14.06 13 15870 1237 110572179
Corneal epithelium defect 42.35 14.06 12 15871 900 110572516
Ocular hyperaemia 40.15 14.06 38 15845 39248 110534168
Cataract 39.84 14.06 53 15830 79432 110493984
Encephalopathy 39.03 14.06 53 15830 81002 110492414
Psychotic disorder due to a general medical condition 38.94 14.06 9 15874 297 110573119
Acute generalised exanthematous pustulosis 38.87 14.06 29 15854 21635 110551781
Infusion related reaction 37.86 14.06 5 15878 381157 110192259
Laryngeal haematoma 37.07 14.06 8 15875 192 110573224
Non-cardiogenic pulmonary oedema 36.96 14.06 13 15870 1971 110571445
Thrombocytopenia 36.83 14.06 122 15761 348763 110224653
Eye inflammation 35.73 14.06 20 15863 9151 110564265
Hyperacusis 35.39 14.06 14 15869 2938 110570478
Keratitis 33.95 14.06 16 15867 5128 110568288
Corneal disorder 33.54 14.06 13 15870 2584 110570832
Keratolysis exfoliativa acquired 33.43 14.06 5 15878 11 110573405
Hepatitis 33.34 14.06 52 15831 90002 110483414
Eye irritation 31.62 14.06 31 15852 33421 110539995
Skin hyperpigmentation 31.28 14.06 18 15865 8678 110564738
Stevens-Johnson syndrome 31.10 14.06 36 15847 46865 110526551
Corneal erosion 30.12 14.06 8 15875 471 110572945
Periodontal disease 29.27 14.06 11 15872 2011 110571405
Chronic fatigue syndrome 29.07 14.06 10 15873 1419 110571997
Weight increased 28.98 14.06 12 15871 419632 110153784
Synovitis 28.68 14.06 3 15880 274089 110299327
Renal necrosis 28.25 14.06 7 15876 312 110573104
Retinal oedema 27.80 14.06 10 15873 1617 110571799
Rash morbilliform 27.39 14.06 16 15867 7935 110565481
Renal failure 26.40 14.06 82 15801 226492 110346924
Gamma-glutamyltransferase increased 26.40 14.06 38 15845 61271 110512145
Vitritis 26.38 14.06 11 15872 2642 110570774
Visual impairment 26.26 14.06 59 15824 134369 110439047
Face oedema 26.16 14.06 28 15855 33441 110539975
Prostatitis 25.87 14.06 13 15870 4788 110568628
Purpura 25.71 14.06 24 15859 24364 110549052
Conjunctivitis 24.21 14.06 27 15856 33765 110539651
Distal intestinal obstruction syndrome 24.11 14.06 8 15875 1017 110572399
Corneal thinning 24.05 14.06 6 15877 275 110573141
Dermatitis bullous 23.98 14.06 20 15863 17509 110555907
Conjunctival hyperaemia 23.49 14.06 13 15870 5818 110567598
Wound 23.45 14.06 3 15880 234434 110338982
Vitreous haemorrhage 23.41 14.06 12 15871 4608 110568808
Fibrin 23.34 14.06 4 15879 26 110573390
Eye infection 22.89 14.06 18 15865 14500 110558916
Motion sickness 22.87 14.06 8 15875 1193 110572223
Vitreous floaters 22.87 14.06 15 15868 9119 110564297
Peripheral swelling 22.79 14.06 15 15868 404019 110169397
Corneal graft rejection 22.78 14.06 5 15878 130 110573286
Sudden infant death syndrome 22.76 14.06 6 15877 343 110573073
Swelling 22.72 14.06 11 15872 351030 110222386
Idiopathic orbital inflammation 22.33 14.06 6 15877 369 110573047
Illusion 22.26 14.06 9 15874 1998 110571418
Conjunctival bleb 22.16 14.06 5 15878 148 110573268
Muscle atrophy 22.13 14.06 17 15866 13237 110560179
Necrosis 22.11 14.06 16 15867 11390 110562026
Retinal vasculitis 22.08 14.06 9 15874 2040 110571376
Iridocyclitis 21.63 14.06 12 15871 5396 110568020
Mobility decreased 21.56 14.06 4 15879 237418 110335998
Drug interaction 21.50 14.06 134 15749 500049 110073367
Keratoplasty 21.47 14.06 3 15880 3 110573413
Sinonasal papilloma 21.46 14.06 4 15879 44 110573372
Cross sensitivity reaction 21.31 14.06 12 15871 5555 110567861
Hyperbilirubinaemia 21.11 14.06 24 15859 30647 110542769
Photophobia 20.92 14.06 22 15861 25749 110547667
Anterior segment ischaemia 20.78 14.06 4 15879 53 110573363
Non-infectious endophthalmitis 20.73 14.06 6 15877 485 110572931
Haematoma 20.58 14.06 33 15850 58443 110514973
Cutaneous vasculitis 20.54 14.06 16 15867 12713 110560703
Joint swelling 20.52 14.06 20 15863 442825 110130591
Confusional state 20.42 14.06 126 15757 468554 110104862
Pancytopenia 20.08 14.06 71 15812 209542 110363874
Dermatitis exfoliative 19.93 14.06 15 15868 11332 110562084
Acute febrile neutrophilic dermatosis 19.87 14.06 11 15872 4925 110568491
Upper airway obstruction 19.71 14.06 8 15875 1794 110571622
Delusion of reference 19.62 14.06 5 15878 250 110573166
Tuberculoma of central nervous system 19.38 14.06 6 15877 611 110572805
Periodontitis 19.32 14.06 11 15872 5197 110568219
Dizziness 19.32 14.06 45 15838 698148 109875268
Mucosal erosion 19.31 14.06 9 15874 2815 110570601
Drug intolerance 19.26 14.06 18 15865 406494 110166922
Immune reconstitution inflammatory syndrome 19.12 14.06 17 15866 16209 110557207
Contusion 19.03 14.06 5 15878 233356 110340060
Hepatitis acute 18.88 14.06 18 15865 18748 110554668
Device issue 18.81 14.06 24 15859 34511 110538905
Gastroenteritis staphylococcal 18.51 14.06 5 15878 314 110573102
Fatigue 18.50 14.06 101 15782 1215857 109357559
Pudendal canal syndrome 18.34 14.06 3 15880 14 110573402
Red blood cell vacuolisation 18.17 14.06 3 15880 15 110573401
Ecchymosis 18.15 14.06 17 15866 17321 110556095
Staphylococcal infection 17.52 14.06 34 15849 69910 110503506
Reversible cerebral vasoconstriction syndrome 17.51 14.06 10 15873 4751 110568665
Alopecia 17.45 14.06 16 15867 364737 110208679
Transaminases increased 17.35 14.06 32 15851 63358 110510058
Pericarditis 17.29 14.06 5 15878 219109 110354307
Vasculitis necrotising 17.22 14.06 7 15876 1576 110571840
Aortic dissection 17.18 14.06 10 15873 4923 110568493
Henoch-Schonlein purpura 17.10 14.06 9 15874 3648 110569768
Sideroblastic anaemia 16.82 14.06 5 15878 444 110572972
Neuropathy peripheral 16.54 14.06 60 15823 179217 110394199
Maternal exposure during pregnancy 16.47 14.06 8 15875 254875 110318541
No adverse event 16.23 14.06 34 15849 73805 110499611
Glaucoma 16.14 14.06 18 15865 22499 110550917
Orchitis 16.12 14.06 7 15876 1855 110571561
Eyelid oedema 16.05 14.06 15 15868 15247 110558169
Hyphaema 15.94 14.06 6 15877 1101 110572315
Abdominal pain upper 15.90 14.06 16 15867 349095 110224321
Abdominal discomfort 15.82 14.06 20 15863 393838 110179578
Muscle contractions involuntary 15.46 14.06 9 15874 4435 110568981
Hepatic enzyme increased 15.44 14.06 14 15869 320878 110252538
Anterior chamber flare 15.43 14.06 4 15879 214 110573202
Tendon discomfort 15.38 14.06 5 15878 596 110572820
Pupillary block 15.23 14.06 3 15880 45 110573371
Blindness unilateral 15.14 14.06 12 15871 9774 110563642
Anaemia 15.14 14.06 132 15751 546954 110026462
Oral herpes 15 14.06 22 15861 36058 110537358
Persecutory delusion 14.95 14.06 10 15873 6281 110567135
Conjunctival erosion 14.81 14.06 4 15879 251 110573165
Type I hypersensitivity 14.80 14.06 10 15873 6383 110567033
Conjunctival retraction 14.52 14.06 3 15880 58 110573358
Bicytopenia 14.34 14.06 10 15873 6714 110566702
Contraindicated product administered 14.29 14.06 9 15874 248258 110325158
Tendon injury 14.29 14.06 7 15876 2442 110570974
Hepatitis cholestatic 14.27 14.06 15 15868 17551 110555865
Atrophy 14.25 14.06 7 15876 2457 110570959
Target skin lesion 14.25 14.06 4 15879 290 110573126
Dysaesthesia 14.18 14.06 10 15873 6837 110566579
Anterior chamber inflammation 14.14 14.06 5 15878 770 110572646
Eye discharge 14.12 14.06 11 15872 8743 110564673
Hepatosplenomegaly 14.09 14.06 10 15873 6909 110566507
Toxicity to various agents 14.07 14.06 30 15853 480525 110092891

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01MA01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
QUINOLONE ANTIBACTERIALS
Fluoroquinolones
ATC J01RA09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01RA17 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC J01RA18 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
ATC S01AE01 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Fluoroquinolones
ATC S02AA16 SENSORY ORGANS
OTOLOGICALS
ANTIINFECTIVES
Antiinfectives
FDA CS M0023650 Quinolones
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000892 Anti-Infective Agents, Urinary
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D059005 Topoisomerase II Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
FDA EPC N0000175937 Quinolone Antimicrobial
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50750 EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
CHEBI has role CHEBI:53559 topoisomerase IV inhibitor
CHEBI has role CHEBI:59517 DNA synthesis inhibitor
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

J01MA Fluoroquinolones 22 drugs
ciprofloxacindelafloxacinenoxacinfleroxacingarenoxacingatifloxacingemifloxacingrepafloxacinlascufloxacinlevofloxacinlomefloxacinmoxifloxacin show all 22 →
J01RA Combinations of antibacterials 18 drugs
amikacinazithromycincefepimecefiximecefuroximeciprofloxacinfluconazolelevofloxacinmetronidazolenitazoxanidenorfloxacinnystatin show all 18 →
S01AE Fluoroquinolones 8 drugs
besifloxacinciprofloxacingatifloxacinlevofloxacinlomefloxacinmoxifloxacinnorfloxacintosufloxacin
S02AA Antiinfectives 17 drugs
acetic acidaluminium acetotartrateboric acidcefmenoximechloramphenicolchlorhexidineciprofloxacinclioquinolfosfomycingentamicinhydrogen peroxidemiconazole show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Otitis externa indication 3135009
Typhoid fever indication 4834000 DOID:13258
Septicemia due to Escherichia coli indication 9323009
Prostatitis indication 9713002 DOID:14654
Infection due to Pseudomonas aeruginosa indication 11218009
Gonorrhea indication 15628003 DOID:7551
Enteric campylobacteriosis indication 18081009
Infectious diarrheal disease indication 19213003 DOID:13250
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Acute gonococcal urethritis indication 29864006
Acute bacterial peritonitis indication 31860008
Bronchitis indication 32398004 DOID:6132
Postoperative infection indication 33910007
Pneumonia due to Streptococcus indication 34020007
Shigellosis indication 36188001
Cystitis indication 38822007 DOID:1679
Pneumonia due to Pseudomonas indication 41381004
Gonorrhea of rectum indication 42746002
Pyelonephritis indication 45816000 DOID:11400
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Acute maxillary sinusitis indication 68272006 DOID:2050
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Rhinoscleroma indication 72409005 DOID:11336
Abdominal abscess indication 75100008
Acute bacterial sinusitis indication 75498004
Nongonococcal urethritis indication 84619001
Infective otitis externa indication 86981007 DOID:9463
Chronic tubotympanic suppurative otitis media indication 87665008 DOID:14435
Infection of bone indication 111253001
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Bacterial conjunctivitis indication 128350005 DOID:9700
Infection due to Enterobacteriaceae indication 128945009
Urethritis due to Chlamydia trachomatis indication 179101003
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Chlamydial pelvic inflammatory disease indication 188463006
Acute Moraxella catarrhalis bronchitis indication 195722003
Proteus pneumonia indication 195888009
Malignant otitis externa due to Pseudomonas aeruginosa indication 232230009
Acute bacterial bronchitis indication 233598009
Pneumonia indication 233604007 DOID:552
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Infective cystitis indication 236620008
Chancroid indication 266143009 DOID:13778
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Anthrax indication 409498004 DOID:7427
Acute osteomyelitis indication 409780002
Nosocomial pneumonia indication 425464007
Acute exacerbation of chronic bronchitis indication 425748003
Urinary tract infection caused by Klebsiella indication 369001000119100
Pseudomonas Aeruginosa Urinary Tract Infection indication
Enterobacter Pneumonia indication
Mixed Gonococcal and Chlamydia Infection of the Urethra indication
Complicated Bacteroides Peritonitis indication
Pseudomonas Aeruginosa Cystitis indication
Skin and Skin Structure Serratia Infection indication
Complicated Bacterial Peritonitis indication
Chlamydia Cervicitis indication
Haemophilus Influenzae Chronic Bronchitis indication
Complicated Skin and Skin Structure Proteus Infection indication
Streptococcus Pneumoniae Bronchitis indication
Moraxella Catarrhalis Chronic Bronchitis indication
Chronic Staphylococcus epidermidis Prostatitis indication
Pseudomonas Aeruginosa Osteomyelitis indication
Haemophilus Parainfluenzae Pneumonia indication
Enterobacter Osteomyelitis indication
Providencia Urinary Tract Infection indication
Nosocomial Pneumonia due to Serratia Marcescens indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea indication
Complicated Proteus UTI indication
Chronic Bacterial Prostatitis indication
Gram-Negative Aerobic Bacillary Pneumonia indication
Proteus Prostatitis indication
Staphylococcus Epidermidis Skin and Skin Structure Infection indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection indication
Serratia Joint Infection indication
Skin and Skin Structure Morganella Morganii Infection indication
Complicated Urinary Tract Infections indication
Nosocomial Pneumonia due to Escherichia Coli indication
Skin and Skin Structure Citrobacter Infection indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa indication
Chronic Enterococcus faecalis Prostatitis indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection indication
Colorectal Surgery Infection Prevention indication
Bacterial Corneal Ulcer Infection indication
Legionella Pneumophila Pneumonia indication
Complicated E. Coli Peritonitis indication
Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus indication
Mixed Gonococcal and Chlamydia Infection of the Cervix indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Serratia Urinary Tract Infection indication
Diarrhea due to E. Coli indication
Moraxella Catarrhalis Pneumonia indication
E. Coli Pyelonephritis indication
Serratia Osteomyelitis indication
Staphylococcus Epidermidis Urinary Tract Infection indication
E. Coli Cystitis indication
Enterobacter Cystitis indication
Chronic Escherichia coli Prostatitis indication
Complicated UTI with Pseudomonas Aeruginosa indication
Pseudomonas Aeruginosa Joint Infection indication
Citrobacter Urinary Tract Infection indication
Citrobacter Complicated UTI indication
Skin and Skin Structure Proteus Infection indication
Streptococcus Pneumoniae Chronic Bronchitis indication
Staphylococcus Aureus Otitis Externa indication
Klebsiella Nosocomial Pneumonia indication
Enterococcus Complicated UTI indication
Haemophilus Parainfluenzae Bronchitis indication
Citrobacter Cystitis indication
Enterococcus Urinary Tract Infection indication
Haemophilus Influenzae Bronchitis indication
Staphylococcus Saprophyticus Urinary Tract Infection indication
Staphylococcus Aureus Bronchitis indication
Morganella Morganii Urinary Tract Infection indication
Staphylococcus Cystitis indication
Complicated Klebsiella Peritonitis indication
Nosocomial Pneumonia due to Streptococcus Pneumoniae indication
Complicated Skin and Skin Structure Infection indication
Nosocomial Pneumonia due to Klebsiella Pneumoniae indication
EnterobacterJoint Infection indication
Nosocomial Pneumonia due to Haemophilus Influenzae indication
Skin and Skin Structure Providencia Infection indication
Proteus Cystitis indication
Vaginal Hysterectomy Infection Prevention indication
Inhalational anthrax off-label use 11389007
Traveler's diarrhea off-label use 11840006
Acute tuberculosis off-label use 25629007
Salmonella septicemia off-label use 49786009
Cutaneous anthrax off-label use 84980006 DOID:7426
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Pulmonary tuberculosis off-label use 154283005 DOID:2957
Diverticulitis of gastrointestinal tract off-label use 271366000
Ventilator-acquired pneumonia off-label use 429271009
Diabetic Foot Infection off-label use
Prevention of Meningococcal Meningitis off-label use
Hallucinations contraindication 7011001
Achilles tendinitis contraindication 11654001
Agranulocytosis contraindication 17182001 DOID:12987
Lowered convulsive threshold contraindication 19260006
Torsades de pointes contraindication 31722008
Transplantation of heart contraindication 32413006
Dehydration contraindication 34095006
Tendinitis contraindication 34840004 DOID:971
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Transplant of kidney contraindication 70536003
Diabetes mellitus contraindication 73211009 DOID:9351
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Transplant of lung contraindication 88039007
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Pancytopenia contraindication 127034005 DOID:12450
Superimposed infection contraindication 193198003
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Rhabdomyolysis contraindication 240131006
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Viral ear infection contraindication 312137007
Pseudomembranous enterocolitis contraindication 397683000
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic rupture of tendon contraindication 415749005
Congenital long QT syndrome contraindication 442917000
Severe Cerebral Arteriosclerosis contraindication
Tremors contraindication
Shoulder Tendonitis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.12 acidic
pKa2 8.29 Basic
pKa3 1.12 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter IC50 4.54 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR IC50 4.41 WOMBAT-PK
Histamine H3 receptor GPCR IC50 4.55 WOMBAT-PK
Gamma-aminobutyric acid receptor subunit alpha-2 Ion channel IC50 4.23 WOMBAT-PK
DNA gyrase subunit A Enzyme INHIBITOR IC50 5.28 WOMBAT-PK CHEMBL
DNA gyrase subunit B Enzyme WOMBAT-PK
Gag-Pro-Pol polyprotein Polyprotein IC50 4.82 WOMBAT-PK
GABA-A receptor; anion channel Ion channel IC50 4.96 CHEMBL
CAAX prenyl protease 1 Enzyme AC50 5.71 CHEMBL
Trypsin Enzyme AC50 5.03 CHEMBL

External reference:

IDSource
4019567 VUID
N0000147667 NUI
D00453 KEGG_DRUG
4019567 VANDF
CHEBI:7731 CHEBI
XED PDB_CHEM_ID
CHEMBL4 ChEMBL_ID
10918 IUPHAR_LIGAND_ID
DB01165 DRUGBANK_ID
A4P49JAZ9H UNII
7623 RXNORM
47400 MMSL
5197 MMSL
d00114 MMSL
003563 NDDF
004136 NDDF
387551000 SNOMEDCT_US
441553007 SNOMEDCT_US
96086002 SNOMEDCT_US
C0028902 UMLSCUI
D015242 MESH_DESCRIPTOR_UI
5322 INN_ID
4583 PUBCHEM_CID
118120-51-7 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 0517-0760 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 0517-0761 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 0904-7434 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
OCUFLOX HUMAN PRESCRIPTION DRUG LABEL 1 11980-779 SOLUTION/ DROPS 3 mg OPHTHALMIC NDA 23 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 13985-602 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 25 sections
OFLOXACIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-175 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 10 sections
OFLOXACIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-931 SOLUTION/ DROPS 3 mg AURICULAR (OTIC) ANDA 11 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 17478-713 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 23 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 21695-439 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 19 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 21695-881 SOLUTION/ DROPS 3 mg AURICULAR (OTIC) ANDA 23 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 24208-410 SOLUTION 3 mg AURICULAR (OTIC) ANDA 18 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 24208-434 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 19 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 33261-737 SOLUTION 3 mg AURICULAR (OTIC) ANDA 18 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 42254-257 SOLUTION 3 mg AURICULAR (OTIC) ANDA 18 sections
Ofloxacin Otic HUMAN PRESCRIPTION DRUG LABEL 1 50090-1090 SOLUTION 3 mg AURICULAR (OTIC) ANDA 20 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-1744 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 19 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-3836 SOLUTION/ DROPS 3 mg AURICULAR (OTIC) ANDA 23 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5186 SOLUTION 3 mg OPHTHALMIC ANDA 21 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5209 SOLUTION 3 mg OPHTHALMIC ANDA 21 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5210 SOLUTION 3 mg OPHTHALMIC ANDA 21 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5425 SOLUTION 3 mg OPHTHALMIC ANDA 13 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5670 SOLUTION 3 mg AURICULAR (OTIC) ANDA 19 sections
ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-6794 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-7207 SOLUTION 3 mg AURICULAR (OTIC) ANDA 19 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-7264 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 19 sections
ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50090-7761 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0713 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50436-6112 SOLUTION/ DROPS 3 mg OPHTHALMIC ANDA 19 sections
ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 52959-763 SOLUTION 3 mg OPHTHALMIC ANDA 22 sections
Ofloxacin HUMAN PRESCRIPTION DRUG LABEL 1 53002-1604 SOLUTION 3 mg AURICULAR (OTIC) ANDA 18 sections